The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Henson, S. M.
Right arrow Articles by Aspinall, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Henson, S. M.
Right arrow Articles by Aspinall, R.
The Journal of Immunology, 2005, 175: 4112-4118.
Copyright © 2005 by The American Association of Immunologists

An IL-7 Fusion Protein That Shows Increased Thymopoietic Ability1

Sian M. Henson2,*, Robert Snelgrove{dagger}, Tracy Hussell{dagger}, Dominic J. Wells{ddagger} and Richard Aspinall*

* Department of Immunology, Imperial College, Chelsea and Westminster Hospital, London, United Kingdom; {dagger} Kennedy Institute, Imperial College, London, United Kingdom; and {ddagger} Gene Targeting Unit, Department of Cellular and Molecular Neuroscience, Imperial College, Charing Cross Hospital, London, United Kingdom

The role of IL-7 during thymopoiesis has led to it being the focus of a number of therapeutic interventions. However, its small size and pleiotropic nature present problems for thymus-directed therapies. We have created a fusion molecule between the extracellular N-terminal domain of CCR9 and IL-7, which has the potential to overcome these difficulties. This novel fusion protein retains the thymopoietic activity of IL-7 and the ligand-binding ability of CCR9. As a thymopoietic agent, compared with IL-7, it shows an enhanced retention in the thymus, increased de novo T cell production, and increased thymic output. Old mice receiving the fusion protein show improved CD8 T cell responses and reduced viral load after infection with influenza virus compared with those receiving IL-7. This chimeric molecule offers a novel therapeutic strategy that may result in the production of an effective immunorestorative agent.




This article has been cited by other articles:


Home page
J. Immunol.Home page
S. M. Eaton, A. C. Maue, S. L. Swain, and L. Haynes
Bone Marrow Precursor Cells from Aged Mice Generate CD4 T Cells That Function Well in Primary and Memory Responses
J. Immunol., October 1, 2008; 181(7): 4825 - 4831.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.